Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a leading global pharmaceutical company headquartered in Bridgewater, NJ. Amneal develops, manufactures, and distributes a diverse portfolio of over 280 generic and specialty pharmaceutical products across the United States, India, and Ireland. With a commitment to providing affordable medicines, Amneal operates through three key segments: Generics, Specialty, and AvKARE.
Generics Segment: This segment focuses on producing a wide range of dosage forms and delivery systems, including injectables and biosimilars, contributing significantly to the company's revenue. The Generics segment is dedicated to expanding across complex product categories and therapeutic areas, ensuring patients have access to vital medications.
Specialty Segment: Amneal's Specialty segment promotes proprietary branded pharmaceuticals targeting central nervous system and endocrine disorders. The segment has a growing portfolio of branded pharmaceuticals with a pipeline focused on addressing unmet medical needs, demonstrating the company's commitment to innovation.
AvKARE Segment: This segment distributes pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution. AvKARE focuses on offering consistent care and pricing to qualified entities, enhancing access to essential medicines for governmental and institutional markets.
Recently, Amneal has achieved significant milestones, including the resubmission of a Complete Response to the FDA for IPX203, an oral formulation for Parkinson’s disease, and entering a licensing agreement with Zambon Biotech for IPX203 in Europe. The company also launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, underscoring their commitment to oncology treatment advancements.
Amneal's financial performance remains robust, with net revenue of $2.39 billion in 2023 and a strategic focus on expanding its reach through innovative products and international partnerships. The company continuously invests in research and development to meet the growing demands for affordable and high-quality medications, solidifying its position as a key player in the pharmaceutical industry. For more information, please visit www.amneal.com.
Amneal Pharmaceuticals (NYSE: AMRX) announced the FDA's acceptance of its Biologics License Application (BLA) for Bevacizumab, a biosimilar to Avastin, with a standard review goal date in Q2 2022. Developed with mAbxience, Bevacizumab targets metastatic colorectal cancer and had U.S. sales of approximately $2.8 billion in the past year. The biosimilar Alymsys has already been approved in Europe. This milestone supports Amneal's strategy to enhance its biosimilar portfolio, which includes other products like Filgrastim and Pegfilgrastim.
Amneal Pharmaceuticals (NYSE: AMRX) announced that the FDA accepted its 505(b)(2) New Drug Application for a dihydroergotamine (DHE) prefilled syringe autoinjector. A decision is expected by mid-2022, with a potential launch in the second half of 2022. This product aims to provide patients with an easy-to-use self-administration method for acute migraine and cluster headaches. DHE's current U.S. sales are around $70 million annually, indicating a significant market opportunity. Amneal's strategy includes leveraging its existing commercial infrastructure in neurology.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in two investor conferences. The RBC Global Healthcare Conference will be held on May 18, 2021, featuring a fireside chat at 1:55 p.m. ET. The Goldman Sachs 42nd Annual Global Healthcare Conference is scheduled for June 10, 2021, with a fireside chat at 3:50 p.m. ET. Both events will be accessible via live webcast on the Company's Investor Relations webpage. Amneal focuses on the development and distribution of generics and specialty products and holds a 65% stake in AvKARE.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) reported net revenue of $493 million for Q1 2021, a 1% decrease from $499 million in Q1 2020. The decline was attributed to reduced influenza activity and prior year customer purchases due to COVID-19. Net income fell to $7 million from $115 million, impacted by a $110 million tax benefit in 2020. Adjusted EBITDA was $126 million, down 6%. However, Amneal maintains its full-year 2021 guidance: net revenue of $2.1-$2.2 billion and adjusted diluted EPS of $0.70-$0.85.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2021 financial results on May 7, 2021, before market open. A conference call will be held at 8:30 a.m. Eastern Time on the same day, accessible via the Investor Relations section of their website. Access the call at (844) 746-0741 for U.S. callers or (412) 317-5273 internationally. A replay will be available for seven days after the call. Amneal focuses on the development and distribution of generic and specialty pharmaceuticals, with significant operations in North America, Asia, and Europe.
Amneal Pharmaceuticals (NYSE: AMRX) has completed the acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, enhancing its portfolio in complex generics and innovative drug delivery platforms. This move strengthens Amneal's R&D capabilities by integrating Kashiv's experienced team known for successful products like Yuvafem and EluRyng. The acquisition aligns with Amneal's strategy to evolve into a more integrated pharmaceutical company.
Amneal Pharmaceuticals (NYSE: AMRX) reported strong financial results for Q4 and full year 2020, with Q4 revenue at $510 million, a 28% increase year-over-year. The annual revenue reached $1.993 billion, up 23%. The company's net loss for Q4 improved to $3 million from $32 million in 2019, while net income for the year was $91 million compared to a loss of $362 million in 2019. Looking ahead, Amneal forecasts 2021 revenues between $2.1 billion and $2.2 billion and adjusted diluted EPS of $0.70 to $0.85, reflecting continued growth in the Generics and Specialty markets.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in two upcoming investor conferences: the Raymond James Institutional Investors Conference on March 1, 2021, at 3:00 p.m. ET, and the Barclays Global Healthcare Conference on March 10, 2021, at 4:10 p.m. ET. Both events will include fireside chats and can be accessed via a live webcast on the Company's Investor Relations website. Amneal focuses on developing and distributing generic and specialty pharmaceuticals, boasting around 250 product families, and operates globally, including a majority stake in AvKARE, which supplies pharmaceuticals to government agencies.
Amneal Pharmaceuticals (NYSE: AMRX) is set to release its fourth quarter and full year 2020 financial results on February 26, 2021, before market open. A conference call and live webcast will take place at 8:30 a.m. ET that day, accessible via the Investor Relations section of Amneal's website. Participants can join by dialing (844) 746-0741 in the U.S. or (412) 317-5273 internationally. A replay will be available for seven days at (877) 344-7529 for U.S. callers and (412) 317-0088 for international callers, using access code 10152029.
Amneal Pharmaceuticals (NYSE:AMRX) has announced a definitive agreement to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, enhancing its growth strategy. The $70 million upfront payment, plus $30 million after a year and potential contingent payments of $8 million, aims to boost Amneal's pipeline in neurology and endocrinology. This acquisition is expected to deliver approximately $15 million in annual adjusted EBITDA. The deal strengthens Amneal's R&D capabilities and is expected to close in Q2 2021, subject to regulatory approval.
FAQ
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
What is the market cap of Amneal Pharmaceuticals (AMRX)?
What does Amneal Pharmaceuticals, Inc. specialize in?
What are the key segments of Amneal Pharmaceuticals?
Where is Amneal Pharmaceuticals headquartered?
What recent product has Amneal Pharmaceuticals launched in the oncology space?
What is the significance of Amneal's IPX203?
How does Amneal Pharmaceuticals contribute to the U.S. pharmaceutical market?
What financial performance did Amneal achieve in 2023?
How is Amneal addressing the opioid crisis?
What are some key partnerships of Amneal Pharmaceuticals?
How can investors get more information about Amneal Pharmaceuticals?
